Wellstar Health System and Augusta University Health System Announce Definitive Agreement for Statewide Partnership
On March 31, 2023, Wellstar Health System and Augusta University Health System (AUHS), with approval from both organizations’ boards, reached an agreement to form an innovative, new partnership that will create a broader affiliation with the university’s Medical College of Georgia (MCG).
Wellstar, AUHS and MCG share a mission to solve health care challenges across the state, and together, they will drive significant advances in clinical care, academic teaching and research in Georgia. By combining the best of community health care and academic medicine, the organizations will make a transformational impact on improving the health and wellbeing of each patient they serve – creating a healthier future for Georgia.
To accomplish this, the partnership will focus on five key areas:
- Access to Expertise: Creating an ecosystem of care that provides the most advanced clinical care, innovated academic teaching models, and lifesaving research to all corners of the state and beyond.
- Expanding the Pipeline of Clinicians: Making significant investments to increase the number of clinicians trained in Georgia at the Medical College of Georgia.
- Care Innovation: Creating new and innovative clinical care offerings and models to enhance the health and well-being of patients we serve.
- Pediatric Care: Bringing Wellstar and AUHS’s exemplary pediatric care to more Georgians across the state through Children’s Hospital of Georgia and Wellstar’s dedicated pediatric care and emergency departments.
- Digital Health: Making significant investments in improving clinical IT, modernizing digital care centers, and adding remote care offerings backed by the academic medical expertise of the Medical College of Georgia.
Most of the day-to-day operations will stay the same, and patients will continue to access care as they currently do. The organizations are excited for the benefits this partnership will provide and are confident about the opportunity to transform health care through a better patient experience, more accessible care and better value.
For more information, read the full announcement here.
“Evolving FTC and DOJ policies leave investors and innovators navigating a cautious M&A landscape
Atlanta, GA — October 6 — Georgia Life Sciences today announced the launch of Vitals, a new podcast series developed in partnership with Cloudcast Media, a leader in branded podcast production. The series will spotlight the people, ideas, and innovations shaping the future of Georgia’s rapidly growing life sciences sector. Hosted by Georgia Life Sciences’ CEO, Maria Thacker Goethe, Vitals will feature in-depth conversations with scientists, entrepreneurs, investors, educators, policymakers, and patient advocates. Each episode will explore the challenges and opportunities facing Georgia’s life sciences ecosystem—spanning biopharma, medical technology, digital health, and advanced manufacturing. “Vitals gives us a powerful platform to showcase the remarkable work happening within our state,” said Maria Thacker Goethe. “By sharing these stories, we’re highlighting not only groundbreaking science but also the collaboration and talent that make Georgia such a vibrant hub for health innovation.” Cloudcast Media, known for its expertise in storytelling and high-quality podcast production, will bring industry insights and technical support to ensure the series reaches audiences across Georgia and beyond. “We’re proud to partner with Georgia Life Sciences on Vitals,” said Charles Parisi, Founder and CEO of Cloudcast. “This series will elevate the voices of innovators who are advancing science, improving patient outcomes, and building Georgia’s reputation as a global life sciences leader. We are very excited that Cloudcast Atlanta can play a role in supporting Maria and the impactful work of Georgia Life Sciences.” The first episode of Vitals launched today and is available on Apple Podcasts, Spotify, and other major streaming platforms, as well as through the Georgia Life Sciences website.
September 30, 2025 WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, Americans have subsidized the research and development necessary to bring newer and better medicines to patients around the world. As we saw with defense spending and NATO, the solution is not to weaken a strategically important American industry, but for other countries to pay their fair share. “Today’s announcement in the Oval Office highlights the problems with a drug delivery system where half of the cost of innovative medicines goes to middlemen and distributors, and where the supply chain distorts prices paid by the American people. We support a new framework that addresses the cost of medicines by simplifying the system - and making medicines directly available to patients. “But importing socialist price controls through most-favored nation policies fundamentally does not address the imbalance in international pricing for innovative medicines. MFN will not lower the out-of-pocket prices that most Americans pay for medicines. Even worse, it will jeopardize the entrepreneurial spirit and deter the capital necessary for a vibrant and essential American biotechnology industry to thrive and may cause most harm to small and midsize biotech companies, which are responsible for discovering more than half of all new treatments. “Without these biotech innovators and a free-market system, we risk slower scientific progress, decreased access to new medicines, compromised national security, fewer American jobs and perhaps most tragically, a diminished hope for those suffering with illness and disease. There are much better ways to address this problem than MFN.” ###
